282 results on '"Berrino, Enrico"'
Search Results
2. Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition
3. High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue
4. Author Correction: scCircle-seq unveils the diversity and complexity of extrachromosomal circular DNAs in single cells
5. scCircle-seq unveils the diversity and complexity of extrachromosomal circular DNAs in single cells
6. Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres
7. Enhancing breast cancer screening with urinary biomarkers and Random Forest supervised classification: A comprehensive investigation
8. Alternative Tissue Fixation Protocols Dramatically Reduce the Impact of DNA Artifacts, Unraveling the Interpretation of Clinical Comprehensive Genomic Profiling
9. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
10. Plasma microRNA ratios associated with breast cancer detection in a nested case–control study from a mammography screening cohort
11. Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)
12. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
13. Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment.
14. Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas
15. Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors
16. Correction to: Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)
17. MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer
18. Comprehensive Molecular Profiling of NPM1-Mutated Acute Myeloid Leukemia Using RNAseq Approach
19. Evaluation of global and intragenic hypomethylation in colorectal adenomas improves patient stratification and colorectal cancer risk prediction
20. COVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance
21. Correction to: Evaluation of global and intragenic hypomethylation in colorectal adenomas improves patient stratification and colorectal cancer risk prediction
22. High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue.
23. Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer
24. High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue
25. Whole exome sequencing in the differential diagnosis of Diamond-Blackfan anemia: Clinical and molecular study of three patients with novel RPL5 and mosaic RPS19 mutations
26. Emerging prognostic biomarkers in advanced cutaneous melanoma: a literature update.
27. Alternative protocols of tissue fixation dramatically reduces the impact of DNA artifacts, unraveling the interpretation of clinical Comprehensive Genomic Profiling
28. Figure S3 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
29. Supplementary Table S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
30. Supplementary Methods from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
31. Data from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
32. BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
33. Abstract 6224: Exploring the integration of CMS subtyping and other omics in colorectal cancer classification and its reflection in stool miRNome and metagenome for non-invasive precision medicine
34. Figure S2 from HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
35. Table S2 from HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
36. Supplementary Data 3 from Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer
37. Supplementary Data 1 from Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer
38. Data from Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer
39. uncropped western blot gels from Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer
40. Supplementary Data 4 from Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer
41. Supplementary Data 2 from Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer
42. Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient
43. Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features
44. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance
45. Correction to: Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)
46. HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
47. Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)
48. The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment
49. Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST
50. DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.